Table 3. Therapeutic barrier of first line ARV regimens using Stanford Algorithm.
| ARV regimen | Genotypic Sensitivity Score | |||||
| <3 | ≤2 | |||||
| n | (%) | n | (%) | |||
| EFV | TDF | FTC/3TC | 155 | (5.6) | 94 | (3.4) |
| ABC | FTC/3TC | 157 | (5.7) | 95 | (3.4) | |
| NVP | TDF | FTC/3TC | 169 | (6.1) | 109 | (3.9) |
| ABC | FTC/3TC | 171 | (6.2) | 109 | (3.9) | |
| LPV | TDF | FTC/3TC | 64 | (2.3) | 20 | (0.7) |
| ABC | FTC/3TC | 68 | (2.5) | 20 | (0.7) | |
| ATZ | TDF | FTC/3TC | 72 | (2.6) | 25 | (0.9) |
| ABC | FTC/3TC | 75 | (2.7) | 26 | (0.9) | |
| DRV | TDF | FTC/3TC | 61 | (2.2) | 19 | (0.7) |
| ABC | FTC/3TC | 65 | (2.3) | 19 | (0.7) | |
* Threshold of the genotypic sensitivity score (GSS) used to consider the strain as resistant to a given ARV combination. TDF: tenofovir; ABC: abacavir; 3TC: lamivudine; FTC: emtricitabine; EFV: efavirenz; NVP: nevirapine; LPV: lopinavir; DRV: darunavir; ATZ: atazanavir.